Bradley Schmitz, MD
Internal Medicine · Tacoma, WANPI 1447273990
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 267 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 9.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,848 and has fallen 97.7% since, to $67 in 2024. Among internal medicine clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 267 payments — averaging $12.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$324
- Boehringer Ingelheim$285
- Amgen$273
- Pfizer$249
- Novo Nordisk$213
- AstraZeneca$193
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,297100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 38 | $324 |
| Boehringer Ingelheim | 21 | $285 |
| Amgen | 25 | $273 |
| Pfizer | 38 | $249 |
| Novo Nordisk | 12 | $213 |
| AstraZeneca | 11 | $193 |
| Merck | 22 | $158 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $154 |
| Neurocrine Biosciences, Inc. | 1 | $134 |
| Daiichi Sankyo Inc. | 8 | $133 |
| AbbVie(2 entities) | 7 | $120 |
| Lilly USA, LLC | 12 | $115 |
| Sunovion Pharmaceuticals Inc. | 8 | $114 |
| Sanofi-aventis U.S. LLC | 6 | $103 |
| Avanir Pharmaceuticals, Inc. | 4 | $74 |
| GSK | 4 | $74 |
| Novartis | 4 | $69 |
| Bayer | 1 | $67 |
| Genentech USA, Inc. | 3 | $62 |
| Astellas Pharma US Inc | 3 | $58 |
| Amarin Pharma, Inc. | 3 | $47 |
| Regeneron Healthcare Solutions, Inc. | 2 | $46 |
| Antares Pharma, Inc. | 3 | $36 |
| Ironwood Pharmaceuticals, Inc | 2 | $35 |
| Bausch Health US, LLC | 2 | $34 |
| Collegium Pharmaceutical, Inc. | 2 | $29 |
| Intuitive Surgical | 1 | $29 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Philips North America LLC | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $13 |
How this compares
$3,297 in reported general payments places this provider in the 90th percentile of 2,038 internal medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 239 | $67,171 |
| GlatopaGlatiramer Acetate | 23 | $32,166 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $31,213 |
| JardianceEmpagliflozin | 73 | $23,896 |
| TrulicityDulaglutide | 21 | $22,226 |
| XareltoRivaroxaban | 81 | $21,933 |
| MyrbetriqMirabegron | 51 | $11,822 |
| Spiriva RespimatTiotropium Bromide | 19 | $11,125 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $10,696 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 34 | $10,642 |
| Atorvastatin Calcium | 589 | $10,169 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,692 |
| Gabapentin | 286 | $6,771 |
| Baclofen | 122 | $6,564 |
| Lamotrigine | 29 | $5,495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $249 | $77,813273 claims |
| GSKAnoro Ellipta, Incruse Ellipta, Trelegy Ellipta | $74 | $50,601102 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $285 | $35,02292 claims |
| Lilly USA, LLCTrulicity, Olanzapine | $115 | $23,60357 claims |
| Johnson & JohnsonXarelto | $324 | $21,93381 claims |
| Astellas Pharma US IncMyrbetriq | $58 | $11,82251 claims |
| AstraZenecaFarxiga | $193 | $3,86313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,038 internal medicine providers in Washington.
Other internal medicine in Tacoma
- Royce MorrisonTacoma$72K
- Jon RuckleTacoma$58K
- Daniel GinsbergTacoma$6K
- Peter ShalitSeattle$1M
- Lawrence LoebBellevue$784K
- Shawna PurcellOlympia$294K
- Scott RamseySeattle$230K
- Michael CairnsSeattle$144K
- Peiqing QianSeattle$117K
- Alan KellySpokane Valley$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.